Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Theoretical model of bidirectional relationship of cardiovascular disease (CVD) and cancer.

References

  1. 1.

    Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep. 2016;64:1–119.

    PubMed  Google Scholar 

  2. 2.

    Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–14.

    Article  Google Scholar 

  3. 3.

    Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, et al. Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol. 2013;62:881–6.

    Article  Google Scholar 

  4. 4.

    Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34:1122–30.

    CAS  Article  Google Scholar 

  5. 5.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

    Article  Google Scholar 

  6. 6.

    Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.

    CAS  Article  Google Scholar 

  7. 7.

    Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 2010;53:88–93.

    Article  Google Scholar 

  8. 8.

    Akam-Venkata J, Franco VI, Lipshultz SE. Late cardiotoxicity: issues for childhood cancer survivors. Curr Treat Options Cardiovasc Med. 2016;18:47.

    Article  Google Scholar 

  9. 9.

    Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394:1041–54.

    Article  Google Scholar 

  10. 10.

    Fidler MM, Reulen RC, Winter DL, Kelly J, Jenkinson HC, Skinner R, et al. Long term cause specific mortality among 34 489 five year survivors of childhood cancer in Great Britain: population based cohort study. BMJ. 2016;354:i4351.

  11. 11.

    Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.

    CAS  Article  Google Scholar 

  12. 12.

    El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharm. 2013;170:712–29.

    CAS  Article  Google Scholar 

  13. 13.

    Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596–604.

    CAS  Article  Google Scholar 

  14. 14.

    Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol. 2019;1:238–51.

    Article  Google Scholar 

  15. 15.

    Libby P, Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology. Cardiovasc Res. 2019;115:824–9.

    CAS  Article  Google Scholar 

  16. 16.

    Hasin T, Gerber Y, Weston SA, Jiang R, Killian JM, Manemann SM, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. J Am Coll Cardiol. 2016;68:265–71.

    Article  Google Scholar 

  17. 17.

    Lau E, Paniagua SM, Liu E, Jovani M, Li S, Takvorian K, et al. Abstract 12269: The Association of Cardiovascular Disease and Future Cancer. Circulation. 2019;140(Suppl_1):A12269-A.

  18. 18.

    Rasmussen-Torvik LJ, Shay CM, Abramson JG, Friedrich CA, Nettleton JA, Prizment AE, et al. Ideal cardiovascular health is inversely associated with incident cancer: the atherosclerosis risk in communities study. Circulation. 2013;127:1270–5.

    Article  Google Scholar 

  19. 19.

    Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gregory Y. H. Lip.

Ethics declarations

Conflict of interest

HE has nothing to declare. GYHL reports consultancy and speaker fees from Bayer, Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo outside the submitted work. No fees received personally. ARP has received research funding from AstraZeneca, Celgene, Chugai, Gilead, GSK/Novartis, Napp and Roche and speaker fees and hospitality from Celgene, Gilead and Roche. The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Essa, H., Pettitt, A.R. & Lip, G.Y.H. Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated. J Hum Hypertens (2020). https://doi.org/10.1038/s41371-020-00400-8

Download citation

Search

Quick links